Researchers at Children's Hospital of Philadelphia (CHOP) reported long-term clinical outcomes for the largest single center cohort of individuals who underwent complex reconstructive surgery for ...

Longeveron Inc. has completed enrollment for its Phase 2b clinical trial, ELPIS II, which is testing laromestrocel, a cellular therapy aimed at improving outcomes in infants with Hypoplastic Left ...

The Nature Index 2026 Research Leaders reveal the leading institutions and countries/territories in the natural sciences, health sciences, applied sciences and social sciences, according to their ...

Laromestrocel is a proprietary, scalable, allogeneic cellular therapy being evaluated to improve the clinical outcomes of children with HLHS Full enrollment achieved for pivotal Phase 2b clinical ...

KANSAS CITY, Mo. — Evelyn Mitchell was diagnosed with Hypoplastic left heart syndrome, or HLHS, before she was born. “Evelyn had surgery when she was six weeks old, and then she had it again when she ...